Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in ANCA-Associated Vasculitis
NCT01598857Phase 2Withdrawn
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Dec 2014
- Primary completion
- Jun 2015
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Blisibimod Arm with Placebo Arm (2 arms). Primary endpoint: Induction of clinical remission at 24 weeks. Planned start Dec 2014; status: withdrawn.
02
Drugs
blisibimod
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT01598857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598857.